罗氏制药、欧莱雅、LVMH集团、诺华、葛兰素史克涨1.94%-1.09%，阿斯利康、赛诺菲、雀巢至多涨0.79%，德国思爱普Sap则跌0.23%。 | 名称 = | | 代码 : | 最新价 | 开营 | 흥마 | | 涨跌额 = | 涨跌幅 : | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 【 罗氏制药公司 | | ROG | 263.10 | 257.70 | 263.40 | 255.10 | +5.00 | +1.94% | | I | 阿斯麦公司 | ASMIL | 591.70 | 579.90 | 597.00 | 571.20 | +10.80 | +1.86% | | 欧莱雅 | | OREP | 380.80 | 374.75 | 380.80 | 373.70 | +6.30 | +1.68% | | 路易威登 | | LVMH | 499.70 | 490.25 | 501.80 | 486.05 | +6.90 | +1.40% | | * 诺华 | | NOVN | 92.00 | 91.64 | 92.54 ...

Swiss pharma giant Roche Holding AG (RHHBY) posted strong growth in the first quarter of 2025. Sales increased 7% year over year to CHF 15.4 billion and were up 6% at constant exchange rates (CER).(Find the latest earnings estimates and surprises on Zacks Earnings Calendar.)The company reports under two divisions — Pharmaceuticals and Diagnostics. All growth rates mentioned below are on a year-over-year basis and at CER.Sales in the Pharmaceuticals Division were up 8% in the first quarter to CHF 11.9 billio ...

This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as 'believes', 'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks', 'estimates', 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: Any ...

Core Viewpoint - Roche plans to invest $50 billion in the U.S. over the next five years, creating over 12,000 jobs amid concerns about potential new tariffs on pharmaceutical goods from abroad [1]. Group 1: Investment and Job Creation - The investment will create more than 12,000 jobs, including 1,000 directly with Roche and the rest to support new U.S. manufacturing capabilities [1]. - Roche will establish new state-of-the-art research and development (R&D) sites and expand manufacturing facilities in Indiana, Pennsylvania, Massachusetts, and California [2]. Group 2: Research and Development Focus - A new R&D site in Massachusetts will focus on AI research and serve as a hub for research into cardiovascular, renal, and metabolism treatments [2]. Group 3: Manufacturing Expansion - Roche plans to build a new 900,000 square foot manufacturing center to support its expanding portfolio of next-generation weight loss medicines [3]. - Once the new manufacturing capacity investments are complete, Roche expects to export more medicines from the U.S. than it imports [3]. Group 4: Industry Context - Pharmaceutical companies are increasing their U.S. presence in response to threats from President Trump regarding the potential end of the industry's exemption from import tariffs [3][4].

罗氏（Roche）将于未来五年内在美国投资500亿美元用于制药和诊断。（彭博） ...

智通财经4月22日电，跨国制药公司罗氏未来五年将向美国制药与诊断领域投资500亿美元。 ...

USD 50 billion commitment includes new state-of-the art research and development (R&D) sites, new and expanded manufacturing facilities in Indiana, Pennsylvania, Massachusetts and California and an additional site location to be announced soonInvestments will create more than 12,000 new jobs: 1,000 at Roche and more than 11,000 in support of new US manufacturing capabilities Roche already has a significant existing US presence with more than 25,000 employees, 15 R&D centres and 13 manufacturing sites Basel, ...

Roche (RHHBY) announced that the European Commission has approved its lymphoma drug, Columvi (glofitamab), for second-line treatment of relapsed or refractory (R/R) diffuse large B-cell lymphoma (“DLBCL”).The regulatory body in Europe has now approved Columvi in combination with gemcitabine and oxaliplatin (GemOx) for treating R/R DLBCL in adult patients who are not otherwise specified or eligible for autologous stem cell transplant.The approval in the European Union was expected as the Committee for Medici ...

Core Viewpoint - Roche's Columvi® (glofitamab) has received European Commission approval for use in combination with gemcitabine and oxaliplatin (GemOx) for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplant (ASCT) [1][2] Group 1: Approval and Clinical Significance - Columvi is the first bispecific antibody regimen available in Europe for DLBCL patients whose cancer has returned or who did not respond to initial treatment [1][2] - The approval is based on the pivotal phase III STARGLO study, which showed a 41% reduction in the risk of death for patients treated with Columvi plus GemOx compared to MabThera®/Rituxan® plus GemOx [2][3] - The study demonstrated a median overall survival (OS) of 25.5 months for Columvi-treated patients, nearly double the 12.9 months seen with R-GemOx [2][3] Group 2: Patient Population and Treatment Need - Approximately 38,000 people are diagnosed with DLBCL in Europe each year, with about 40% relapsing after first-line treatment [2][8] - Patients with relapsed or refractory DLBCL not eligible for ASCT represent a challenging population, highlighting the urgent need for effective therapies [2][3] - Columvi in combination with GemOx offers an "off-the-shelf" treatment option that is readily available for infusion, allowing for immediate treatment upon cancer recurrence [2][3] Group 3: Mechanism and Development - Columvi is a CD20xCD3 bispecific antibody designed to engage T cells and target B cells, enhancing the immune response against cancer cells [6][9] - Roche is also investigating Columvi in combination with other therapies for previously untreated DLBCL in the phase III SKYGLO study [7][9] - The company has a broad portfolio of hematology medicines and is committed to developing innovative treatment options for blood cancers [9][10]

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.The Trump administration's tariffs came, created mayhem, and then took 90 days off — at least the more severe levies, and excepting China. It has been one of the more bizar ...